<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370084</url>
  </required_header>
  <id_info>
    <org_study_id>ITODG04-01</org_study_id>
    <secondary_id>041026</secondary_id>
    <nct_id>NCT00370084</nct_id>
  </id_info>
  <brief_title>Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia</brief_title>
  <official_title>Effects of Itopride Hydrochloride on Gastric Emptying, Glycaemia and &quot;Meal-related&quot; Symptoms in Patients With Type 1 and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forest Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Itopride is a new compound that is already marketed in Japan and in some countries of Eastern
      Europe under the name of Ganaton. It is used to treat symptoms associated with gastroparesis.
      Due to inadequate gastric emptying, these patients often have symptoms of bloating, nausea
      and vomiting following ingestion of a meal. The goal of this study is to evaluate the effects
      of Itopride on gastric motor function and glycemia in patients with diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a mechanistic study evaluating in a cross-over design the effects of Itopride
      hydrochloride.

      The primary objective of this study is to evaluate the acute effects of itopride
      hydrochloride (200 mg three times daily) on gastric emptying of solid and liquid meal
      components in patients with type 1 and type 2 diabetes mellitus. Secondary objectives are to
      evaluate the effects of itopride hydrochloride on the glycaemic response to a meal,
      &quot;meal-related&quot; upper gastrointestinal symptoms and intragastric meal distribution.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying assessment</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemia, relief of upper gastrointestinal symptoms, intragastric meal distribution</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Itopride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itopride</intervention_name>
    <description>oral, three times daily</description>
    <arm_group_label>Itopride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral, three times daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type-1 and Type-2 diabetic patients

          -  18 to 65 years old

          -  Glycated haemoglobin level (HbA1c) below 9%

          -  Body mass index (BMI) between 18 and 35 kg/m2

        Exclusion Criteria:

          -  Use of medications potentially influencing upper gastrointestinal motility or appetite
             within one week of the study (e.g. prokinetic drugs, macrolide antibiotics)

          -  Exposure to radiation for research purposes during the previous 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Horowitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Adelaide Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Adelaide, Department of Medicine</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2006</study_first_submitted>
  <study_first_submitted_qc>August 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2006</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

